POSTMENOPAUSAL OSTEOPOROSIS MARKET ANALYSIS

Postmenopausal Osteoporosis Market, by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab among Others)), by Route of Administration (Oral, Intravenous Route, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI5479
Pages :339
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Postmenopausal Osteoporosis Market: Key Developments

On June 13, 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company and PT Etana Biotechnologies Indonesia, an Indonesia-based biotechnology company, jointly announced that the Indonesian Food and Drugs Authority (Badan Pengawas Obat dan Makanan) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody drug, for five indications including metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple-negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer(NSCLC), epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC), and cervical cancer(CC).